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Podocytes are highly differentiated and polarized epithelial cells located on the visceral side of the glomerulus. They form an
indispensable component of the glomerular filter, the slit diaphragm, formed by several transmembrane proteins and adaptor
molecules. Disruption of the slit diaphragm can lead to massive proteinuria and nephrotic syndrome in mice and humans.
CD2AP is an adaptor protein that is important for the maintenance of the slit diaphragm. Together with its paralogue, CIN85,
CD2AP belongs to a family of adaptor proteins that are primarily described as being involved in endocytosis and downregula-
tion of receptor tyrosine kinase activity. We have shown that full-length CIN85 is upregulated in podocytes in the absence of
CD2AP, whereas in wild-type cells, full-length CIN85 is not detectable. In this study, we show that full-length CIN85 is postrans-
lationally modified by SUMOylation in wild-type podocytes. We can demonstrate that CIN85 is SUMOylated by SUMO-1, -2,
and -3 and that SUMOylation is enhanced in the presence of CD2AP. Conversion of lysine 598 to arginine completely abolishes
SUMOylation and leads to increased binding of CIN85 to nephrin. Our results indicate a novel role for CD2AP in regulating
posttranslational modification of CIN85.
The adaptor molecules CD2-associated protein (CD2AP) andCbl-interacting protein of 85 kDa (CIN85) belong to a ubiq-
uitously expressed protein family of adaptor molecules that are
involved in a variety of cellular processes, like cell signaling (12, 18,
52), cytoskeletal arrangement (2, 16, 29, 50), and degradative traf-
ficking and endocytosis of receptors (15, 24, 26, 43, 45, 49, 57).
The two proteins show high sequence and structural similarities,
and they both contain three SH3 domains, a proline-rich region,
and a coiled-coil domain (7). However, they appear to have com-
pletely different functional roles.While CD2AP is solely expressed
in its full-length form, multiple CIN85/Ruk isoforms were iden-
tified in various tissues and cell lines, due to alternative splicing
and different promoters (3, 31).
In podocytes CD2AP is expressed at the slit diaphragm, a spe-
cialized intercellular junction between neighboring podocytes
covering the outer surface of the glomerular tuft. CD2AP interacts
with several proteins at the slit diaphragm. One of themajor com-
ponents is nephrin, a transmembrane adhesion protein of the Ig
superfamily. Humans and mice lacking nephrin are born without
intact slit diaphragms and develop massive proteinuria in utero
(22, 40). Mice deficient in CD2AP are born healthy but develop a
rapid-onset nephrotic syndrome at 3 weeks of age and die of renal
failure 6 weeks after birth (44). We have previously demonstrated
that deficiency of CD2AP leads to a differentiation-dependent in-
crease of full-length CIN85 expression, which correlates with a
loss of expression of the slit diaphragm protein nephrin in podo-
cytes. Furthermore, we found that CIN85 is a binding partner of
nephrin and that overexpression of CIN85 leads to increased en-
docytosis of nephrin after growth factor stimulation (48, 49).
Here, we present evidence that CD2AP has a direct influence
on posttranslational modification of full-length CIN85. Small
ubiquitin-related modifier (SUMO) is a transient and reversible
posttranslational protein modifier that plays an important role in
many cellular pathways, including subcellular localization,
protein-protein interaction, transcriptional regulation, activation
of ion channels, and intracellular localization (11, 35, 38, 56).
Vertebrates contain four 100-amino-acid SUMO proteins,
SUMO-1, -2, -3, and -4. Of these, SUMO-1 to -3 are ubiquitously
expressed whereas the recently reported SUMO-4 seems to be
expressedmainly in the kidney, lymphnode, and spleen. SUMO-2
and -3 are nearly identical, whereas SUMO-1 has only 56% iden-
tity with SUMO-2 and -3. SUMOs are similar to ubiquitin in their
three-dimensional structure, and the steps involved in the SUMO
pathway resemble those of the ubiquitin pathway (11, 19). In con-
trast to ubiquitination, SUMOs attach to lysines that are often
found within a small consensus motif, KXE (where  is a large
hydrophobic amino acid and X can be any amino acid) (41).
SUMO modification occurs through an enzymatic pathway
consisting of an E1 activation enzyme (SAE-2/1), an E2-
conjugating enzyme (Ubc9), and a number of E3 ligases. Ubc9
is capable of directly modifying substrates through interaction
with the SUMO conjugation motif KXE (11, 21). This type of
posttranslational modification is an efficient and rapid way of
controlling the activity of a protein. It is well known that post-
translational modifications, such as phosphorylation and ubiq-
uitination, modulate protein interactions (8, 46). There is no
simple way to predict what the functional consequence of a
SUMOylated target will be. One molecular consequence of
SUMOylation is the inhibition of protein-protein interactions.
An example of this is SUMOylation of C-terminal binding pro-
tein (CtBP), which loses its interaction with the PDZ domain of
nNos (28). SUMOylation can also alter the localization, stabil-
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ity, and activity of a protein (11, 35, 38, 56). The ability of
CIN85 to bind to other proteins has been attributed to the
phosphorylation status of its binding partners (20, 25, 42). The
fact that CIN85 is ubiquitinated (mono-, poly-, andmultiubiq-
uitinated) but not degraded by the proteasome has been exten-
sively studied (14, 51). Ubiquitination is not always associated
with the degradation of modified proteins but could also be
involved in regulating the trafficking and enzymatic activities
of a protein (39). SUMOylation and ubiquitination have also
been reported to act either sequentially or in concert to regulate
the function of the substrate protein (4, 17). Until now, it was
unknown how the activity and binding ability of CIN85 are
regulated. In this study, we demonstrate that CIN85 is post-
translationally modified by SUMOylation in the presence of
CD2AP and controls its interaction with nephrin. Since we
previously demonstrated that CIN85 interaction with nephrin
induces nephrin ubiquitination and endocytosis (49), we pro-
pose that this mechanism contributes to the integrity of the slit
diaphragm.
MATERIALS AND METHODS
Phylogenetic analysis.RepresentativeCD2AP andCIN85 genes fromhu-
man, mouse, chicken, zebrafinch, lizard, frog, and zebrafish were down-
loaded from GenBank and used as query sequences to find close relatives
among invertebrates, including hydra, fruit fly, daphnia, tribolium, hon-
eybee, leech, sea urchin, acorn worm, amphioxus, and sea squirt. All se-
quences were aligned using Muscle (http://www.ebi.ac.uk/Tools/msa
/muscle/) (the accession numbers of all genes and alignment are available
upon request) and analyzed with PAUP*: Phylogenetic Analysis Using
Parsimony (and othermethods) 4.0 beta forMacintosh. Distance analysis
used minimum evolution as the optimality criterion (heuristic search
with tree-bisection-reconnection and random-addition sequence with
100 replications) and mean character difference as the distance measure.
Bootstrap analysis used 1,000 replicates.
Skate sequences. Skate (Leucoraja erinacea) CIN85 and CD2AP pro-
tein sequenceswere translated fromcontiguous sequences generated from
a transcriptome assembly of 50.4 million 76-bp single-end RNA-
sequencing reads from an Illumina Genome Analyzer II. The Illumina
RNA-sequencing library wasmade following themanufacturer’s protocol
(Illumina, San Diego, CA) using RNA isolated from six pooled skate stage
20 to 29 embryos (Marine Biological Laboratory,WoodsHole,MA) using
Tri Reagent (Ambion). The transcriptome assembly was made using
CLCBio Genome Workbench version 4.
Antibodies and chemicals.The antibodies that were used forWestern
blotting and immunofluorescence studies were as follows: rabbit anti-
CD2AP, rabbit anti-GAPDH(anti-glyceraldehyde-3-phosphate dehydro-
genase), rabbit anti-histone H1, rabbit antinephrin, normal rabbit IgG,
normal mouse IgG, and Protein A/G Plus Agarose beads (Santa Cruz,
CA); rabbit anti-green fluorescent protein (anti-GFP), rabbit anti-myc,
rabbit anti-Flag, rabbit anti-hemagglutinin (anti-HA), mouse anti-
ubiquitin, rabbit anti-SUMO-1, rabbit anti-SUMO-2/3, and rabbit anti-
Ubc9 (Cell Signaling Technology, Beverly, MA); mouse anti-CIN85 and
rabbit anti-CIN85 (targeting the C terminus; kindly provided by I. Dikic,
Frankfurt, Germany); and Cy3 labeled goat anti-rabbit and donkey anti-
mouse antibodies and fluorescein isothiocyanate (FITC)-labeled donkey
anti-mouse antibodies (Jackson ImmunoResearch Laboratories, Suffolk,
United Kingdom).
Cell lines and culture. Culture of conditionally immortalized mouse
CD2AP/ and CD2AP/ podocytes was performed as described in
reference 48. In brief, to enhance expression of the thermosensitive large T
antigen, cells were cultured at 33°C in the presence of 10 U/ml gamma
interferon (permissive conditions). To induce differentiation, podocytes
were maintained at 37°C for 14 days without gamma interferon, resulting
in the absence of thermosensitive T antigen (nonpermissive conditions).
The medium consisted of RPMI 1640 (Biochrom, Berlin, Germany) con-
taining 10% fetal calf serum (FCS) (PAA, Pasching, Austria), 1%
penicillin-streptomycin (Invitrogen, Carlsbad, CA), and 10 U/ml recom-
binant mouse gamma interferon (Cell Sciences, Canton, MA). Every ex-
perimental setup and result was confirmed in 3 different clones of
CD2AP/ andCD2AP/ podocytes. Human embryonic kidney (HEK)
293 cells (DSMZ, Braunschweig, Germany) were cultured in medium
consisting of Dulbecco’s modified Eagle’s medium (MEM) high glucose
with L-glutamine (PAA, Pasching, Austria) containing 10% fetal bovine
serum (FBS) (PAA, Pasching, Austria) and 1% antibiotic-antimycotic so-
lution (PAA, Pasching, Austria). The cells were inoculated every 3 or 4
days into new medium.
Animals.Targeted disruption and generation of CD2AP-deficient ho-
mozygous mice on a 129/J background is described elsewhere (44). Kid-
ney tissue and glomeruli were harvested from 4-week-old CD2AP/ and
CD2AP/mice.
Western blot analysis.To analyze whole-cell protein lysates from cul-
tured podocytes, cells were lysed on ice in RIPA buffer (50 mM Tris, pH
7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 1% Nonidet P-40, 0.1%
SDS) containing protease inhibitors (Complete mini; Roche, Mannheim,
Germany), 1 mM sodium orthovanadate, 50 mM NaF, and 200 g/liter
okadaic acid. The lysates were centrifuged at 12,000 rpm, and aliquots of
the supernatants were separated by 10% SDS-PAGE and transferred to
polyvinylidene difluoride (PVDF) membranes (Immobilon-P; Millipore,
Bedford, MA). After probing with primary antibodies, antigen-antibody
complexes were detected with horseradish peroxidase-labeled anti-rabbit
and anti-mouse antibodies, respectively, and visualized using enhanced
chemiluminescence reagents (Pierce, Rockford, IL) according to theman-
ufacturer’s protocol. For subcellular fractionation, differentiated podo-
cytes were trypsinized with trypsin-EDTA (Biochrom, Berlin, Germany)
from 10-cm dishes, and fractionation of the membrane, cytosol, and nu-
clear compartments was performed with a subcellular fractionation kit
(Thermo Sciences, Braunschweig, Germany) according to the manufac-
turer’s protocol.
Isolation and processing of glomeruli.Glomeruli were isolated from
kidneys of 4-week old CD2AP/ and CD2AP/ mice using a
sequential-sieving technique with mesh sizes of 180, 100, and 71m. The
fraction collected from the 71-m sieve was identified as glomeruli, re-
suspended in lysis buffer, and disrupted with a Dounce homogenizer by
hand with 50 up and down strokes, and immunoprecipitation (IP) was
performed with the lysates.
RT-PCR analysis. Total RNA was prepared from cultivated murine
podocytes using the RNeasyMini Kit (Qiagen, Hilden, Germany) follow-
ing the protocol recommended by the manufacturer with an additional
step of DNase digestion (RNase-Free DNase Set; Qiagen). One micro-
gram of total RNA was reverse transcribed using oligo(dT) 15, random
primers, and Moloney murine leukemia virus (M-MLV) reverse trans-
criptase (Promega, Mannheim, Germany). The N terminus and C termi-
nus of full-length CIN85 were amplified by standard PCR using 2 l
cDNA as a template. The mouse CIN85 primers m1 (5=-TTCCGCCAAC
TTTCACTCTG-3=, mmn (5=-GGCAGGAAGTCATTTTCCAC-3=), and
mc (5=-TTCACTTCCATCTGCAACCG-3=) were described by Buchman
et al. (3), and m6 (5=-GGCATCCTGGATAAGGACCTC-3=) was de-
scribed by Gaidos et al. (10).
Transfection with siRNAs. Podocytes were subcultured on 10-cm
dishes and cultured under nonpermissive conditions at 33°C. One day
before transfection, the medium was replaced with growth medium
(RPMI medium with 10% FCS) without antibiotics so that the cultures
would be 30 to 50% confluent at the time of transfection. Transfection
with CD2AP small interfering RNA (siRNA) (Santa Cruz, CA) was per-
formed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to
the manufacturer’s protocol. After being kept in an incubator for 6 h at
33°C, the medium was replaced with normal growth medium. The cells
were incubated at 37°C in a CO2 incubator for 72 h and used for experi-
ments.
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Plasmid construction. The coding sequences for the mature human
SUMO-1, SUMO-2, and SUMO-3 were amplified by PCR, cleaved with
BamHI and XhoI, and cloned into BamHI/XhoI-cleaved pcDNA3. pRc/
CMV-HA-Ubc9 was a gift from R. Bernards (Netherlands Cancer Insti-
tute). Mutant Flag-CIN85K598R and GFP-CIN85K598R were generated by
site-directed mutagenesis using PfuUltra II Fusion HS DNA Polymerase
(Agilent, Santa Clara, CA) and the following primers: forward, 5=-CAGC
ACAGAAGGAAAGCCAAGGATGGAGCCAGTGAGC-3=; reverse, 5=-G
CTCACTGCTGGCTCCATCCTTGGCTTTCCTTCTGTGCTG-3=. All
constructs were confirmed by sequencing.
Transfection. The day before transfection, the podocytes were seeded
on cover slides (5,000 cells/slide) for immunofluorescence or on plates
and cultured under permissive conditions. The cells were transfected with
Fugene transfection reagent (Roche, Grenzach, Germany) according to
the manufacturer’s protocol using mouse GFP-CIN85, mouse GFP-
CIN85K598R, and nephrin-SV5. After transfection, the cells were cultured
under nonpermissive conditions in normal growth medium for 72 h. For
transfection of HEK 293 cells, cells were seeded on plates the day before
transfection. After transfection with Flag-tagged mouse CIN85 and
CIN85K598R; mousemyc-CD2AP; untagged SUMO-1,- 2, or -3; enhanced
green fluorescent protein (EGFP)–SUMO-1; andHA-Ubc9, the cells were
cultured in normal growth medium for 48 h.
Immunoprecipitation. HEK 293T cells were transfected as men-
tioned above. Then, the cells were washed carefully with ice-cold
phosphate-buffered saline (PBS) on ice. For lysis, 900 l RIPA buffer (50
mM Tris-HCl, pH 7.5, 200 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1%
Triton, and 0.25% deoxycholate plus protease inhibitors) was added to
the cells. The lysate was incubated for 15 min on ice and centrifuged at
14,000 rpm for 15 min at 4°C, and 50l Flag-tagged beads (50% slurry in
Triton buffer; Sigma, St. Louis, MO) was added to the supernatant and
rotated overhead at 4°C for 1 h to overnight. For IgG control, agarose G
beads and normal mouse IgG were added to the supernatant. After that,
the beads were centrifuged at 3,000 rpm for 1min at 4°C and washed with
RIPA buffer 5 times. Proteins were eluted by boiling the beads in Laemmli
buffer and separated by SDS polyacrylamide gel electrophoresis. Western
blotting was performed using the methods mentioned above. For immu-
noprecipitation from glomerular and podocyte protein lysates, 500 g of
total cell lysate was incubated with 2g anti-SUMO-1 or anti-SUMO-2/3
and agarose A beads in IP buffer (25 mMTris-HCl, pH 7.5, 1 mM dithio-
threitol [DTT], 30 mM MgCl2, 40 mM NaCl, 0.5% NP-40, and protease
inhibitors) and rotated overnight at 4°C. The pellets were washed 3 times
in IP buffer and separated by SDS polyacrylamide gel electrophoresis. For
the isotype-matched control, immunoprecipitation was performed with
normal rabbit IgG.
Immunofluorescence. For fluorescence images, cultured podocytes
were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton
X-100, blockedwith 10%donkey serum, and stainedwith the appropriate
primary antibody or phalloidin-Alexa Fluor 546 overnight. The next day,
the appropriate secondary antibody was incubated for 1 h, and cover
slides were embedded with DAPI (4=,6-diamidino-2-phenylindole) on
slides. For live-cell staining on SV5-nephrin-transfected podocytes, cells
were stained unfixed at 4°C for 1 hwith the appropriate primary antibody.
For cryostaining, kidneys were flushed with PBS and immediately frozen
in tissuemolds containing optimal-cutting-temperature compound. Sec-
tions were blocked with 10% normal donkey serum and stained with the
appropriate primary antibody followed by Cy3-conjugated donkey anti-
mouse or Cy3-conjugated donkey anti-rabbit and fluorescein
isothiocyanate-conjugated donkey anti-guinea pig antibodies (Jackson
ImmunoResearch). The cells were analyzed using a Zeiss Axioplan-2 im-
aging microscope with the scientific image-processing software AxioVi-
sion 4.6 (Zeiss, Jena, Germany).
Statistics. Data are shown as mean SD and were compared by Stu-
dent’s t test. Densitometric analysis was performed with Quantity One
software. Data analysis was performed using Excel statistical software.
Significant differences were accepted when P was0.05.
RESULTS
Phylogenetic analysis of CIN85 and CD2AP. Because the two
molecules have very similar domain structures, we wanted to un-
ravel the evolutionary history of CIN85 and CD2AP in relation to
the origin of podocytes and the vertebrate kidney. To accomplish
this, we conducted a phylogenetic analysis with a representative
sample of vertebrate CIN85 and CD2AP genes and invertebrate
relatives. A minimum evolution analysis (Fig. 1A) strongly sup-
ports the idea that CIN85 and CD2AP are the products of a gene
FIG 1 Phylogenetic and sequence analyses of CIN85 and CD2AP. (A) Phyloge-
netic tree of CD2AP and CIN85 genes in animals. Aminimum evolution analysis
rooted on the gene sequence from Hydra vulgaris (Hvu) strongly supports the
hypothesis (bootstrap values are indicated at the respective nodes; nodes with
values below95%are collapsed intopolytomies) that these twogenes are the result
of a gene duplication event (circle) early in the evolutionary history of vertebrates,
before the split between chondrichthyians (Ler, the skateL. erinacea) and thebony
fish.These twogenes, presumably the result of a genomeduplication events(s), are
related to single-copy genes found throughout the invertebrates, including the
freshwater cnidarianHydra. Note that according to this phylogenetic analysis, this
gene evolved before the evolution of podocytes, a cell type that characterizes the
protostomes and deuterostomes, including vertebrates, but is not found in more
basal animals, including cnidarians. Aca, the lizard Anolis carolinensis; Ame, the
honeybee, Apis melifera; Bfl, the amphioxus Branchiostoma floridae; Cin, the sea
squirtCiona intestinalis; Dre, the zebrafish,Danio rerio; Dpu, the waterfleaDaph-
nia pulex; Gga, the chicken, Gallus gallus; Hro, the leechHelobdella robusta; Hsa,
Homo sapiens; Mmu, the mouse, Mus musculus; Sko, the hemichordate worm
Saccoglossus kowalevskii; Spu, the purple sea urchin, Strongylocentrotus purpuratus;
Tca, the beetleTriboliumcastaneum; Tgu, the zebrafinch,Taeniopygia guttata; Xtr,
the frog Xenopus laevis. (B) Protein domains and regions annotated according to
humanCIN85 (top) and CD2AP (bottom), including three SH3 domains (blue),
a proline-rich region (red), and a predicted coiled-coil region (green).
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duplication event before the split between chondrichthyes
(sharks, rays, and skates) and osteichthyes (bony fish) but after the
split from invertebrates and presumably associatedwith the 2-fold
genome duplication event early in vertebrate evolution (6) (Fig.
1A, circle). Single-copy relatives of this ancestral gene were found
in all major groups of invertebrates, including arthropods, anne-
lids, echinoderms, hemichordates, and invertebrate chordates,
and in no case was more than one gene found in GenBank’s nu-
cleotide repository. Interestingly, a relative of this single-copy
gene was found in hydra, the freshwater cnidarians. Because
podocytes appear to be an evolutionary invention of the bilateri-
ans (i.e., protostomes and deuterostomes) and are not known in
more basal animals, including cnidarians (37) (Fig. 1A), it appears
that the gene evolved before the invention of the podocyte andwas
coopted into a role in kidney function later in evolution.
In the human genome, CIN85 (SH3KBP1) and CD2AP have
different gene structures and multiple alternatively spliced tran-
scripts. According to Ensembl (release 63), human CIN85
(SH3KBP1) spans 354 kb of chromosome X (Xp22.1 to -p21.3,
positions 19552083 to 19905719 of GRCh37) with 58 exons and
has 12 alternatively spliced transcripts, 10 of which encode pro-
teins. The longest protein is 665 amino acids (aa) with amolecular
mass of 73.126 kDa.CD2AP spans 149 kb of chromosome 6 (6p12,
positions 47445525 to 47594999) with 28 exons and five alterna-
tively spliced transcripts, with the longest one encoding the 639-aa
(71.451-kDa) protein. No microRNA genes lie within the introns
of either CIN85 or CD2AP. The longest isoforms of the human
CIN85 and CD2AP proteins both contain three SH3 domains
(Fig. 1B).While CD2AP protein is only detectable as a single band
in cell lysates, all different splice variants of CIN85/Ruk are detect-
able at the protein level in various tissues (3, 31).
The expression profile of the CIN85 protein differs in
CD2AP/ and CD2AP/ podocytes. Previously, we have
shown that full-length CIN85 is strongly expressed in CD2AP/
podocytes, which has detrimental effects on podocyte survival,
leading to decreased antiapoptotic signaling and enhanced endo-
cytosis of nephrin (48, 49). Immunoblotting of total cell lysates of
CD2AP/ and CD2AP/ podocytes revealed multiple molecu-
lar forms of CIN85 identified by a C-terminal antibody (kindly
provided by I. Dikic). The main bands detected have molecular
masses of 130, 85, 70, 56, 34, and 16 kDa. The 85- to 16-kDa
isoforms result from splicing of pre-mRNA (an 85-kDa full-
length form, a 70-kDa form without the first SH3A domain, a
56-kDa form without two SH3 domains, and a 16-kDa form con-
taining only the C-terminal coiled-coil region) (3, 31) (Fig. 2A).
Interestingly, full-length CIN85 with a molecular mass of 85 kDa
is not detectable in CD2AP/ podocytes, in contrast to
CD2AP/ podocytes, where it is strongly expressed. As depicted
by Western blotting, the full-length CIN85 generally migrates in
doublet form. Furthermore, an immunoreactive band of approx-
imately 130 kDa, which also migrates as a doublet, is strongly
expressed in CD2AP/ podocytes, which was previously de-
scribed as posttranslational modification of CIN85 through ubiq-
uitination in other cells (51). Compared to its expression in wild-
type cells, this band is only weakly detectable in CD2AP/
podocytes. A closer analysis revealed that there are several bands
migrating beneath the 130-kDa form (Fig. 2A). Analysis of ubiq-
uitin expression revealed in CD2AP/ and CD2AP/ podo-
cytes an accumulation of ubiquitinated proteins with a high mo-
lecularmass, but in contrast to CD2AP/ podocytes, CD2AP/
podocytes express several bands migrating with a molecular mass
that corresponds to the 130-kDa band. Moreover, a CIN85 form
with a molecular mass of approximately 200 kDa is detectable in
CD2AP/ podocytes. However, densitometric analysis revealed
that this band is not consistently expressed at significant levels in
every probe. One explanation could be that it is an unstable mod-
ified form of CIN85. Expression analysis of CIN85 mRNA by re-
verse transcription (RT)-PCR established previously (3, 10) that
full-length CIN85 mRNA is expressed in both CD2AP/ and
CD2AP/ podocytes (Fig. 2B). Taken together, these data indi-
cate that full-length CIN85 is posttranslationally modified in
CD2AP/ podocytes.
Full-length CIN85 is posttranslationally modified in podo-
cytes in the presence of CD2AP. To confirm that modification of
full-length CIN85 occurs in the presence of CD2AP, we overex-
pressed mCD2AP-myc in CD2AP/ podocytes. Immunoblot
analysis revealed decreased expression of the 85-kDa isoform and
increased expression of the 130-kDa form compared to cells trans-
fected with an empty vector (Fig. 3A). Previously, we showed
differentiation-dependent expression of full-length CIN85 in
CD2AP/ podocytes (48). To demonstrate that expression of the
85-kDa full-length formofCIN85 depends onCD2AP expression,
we inhibited the expression of CD2AP by siRNA in CD2AP/
podocytes. By immunoblotting, we analyzed total cell lysates of
cells treated with a CD2AP siRNA or control siRNA differentiated
for 0, 2, 4, and 8 days. After 4 days of differentiation, we detected
upregulated expression of the 85-kDa form of CIN85 in the ab-
sence of CD2AP expression, which is further enhanced after 8 days
of differentiation. In contrast, cells treated with a control siRNA
show differentiation-dependent upregulated expression of the
130-kDa form of CIN85, whereas the 85-kDa full-length form is
onlyweakly expressed (Fig. 3B).Whenwe performedRT-PCR,we
found that full-length CIN85 mRNA is upregulated in both
CD2AP/ and CD2AP/ podocytes in a differentiation-
dependent manner (Fig. 3C). These results indicate that the 130-
kDa form of CIN85 is posttranslationally modified in podocytes,
which is also dependent on the presence of CD2AP.
CIN85 is modified by SUMO-1, -2, and -3 in vivo. Posttrans-
lational modification of CIN85 via ubiquitination has been de-
scribed previously. Interestingly, CIN85 is ubiquitinated but not
degraded by the proteasome (51). Themass shift of approximately
45 to 50 kDa indicates that ubiquitination cannot be the only
posttranslational modification. Thus, to evaluate whether CIN85
is alsomodified by SUMO in vivo, we performed immunofluores-
cence staining of frozen kidney cortex sections, which revealed
strong expression of CIN85 in glomeruli of 4-week-old diseased
CD2AP/ mice in contrast to CD2AP/ mice. Furthermore,
expression of SUMO-1 and Ubc9 is not restricted to the nucleus
compared to SUMO-2/3, whichmostly show a strong nuclear pat-
tern. Interestingly, colocalization of CIN85 with SUMO-1 and
Ubc9 is very strong in CD2AP/ mice. Although expression of
CIN85 is increased in glomeruli of CD2AP/ mice, colocaliza-
tion of SUMO-1 and Ubc9 is weaker. Ubc9 expression in
CD2AP/ mice appears to even be decreased in regions of the
glomeruli where CIN85 is strongly expressed (Fig. 4A). Immuno-
precipitation experiments from isolated glomeruli show an asso-
ciation of SUMO-1 and SUMO-2/3 with the 130-kDa form of
CIN85 in glomeruli of CD2AP/ mice, whereas glomeruli of
CD2AP/mice showno association ofCIN85with SUMO-1 and
SUMO-2/3 (Fig. 4B). In contrast to immunofluorescence stain-
SUMOylation of CIN85
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ing, there is no difference in the binding of SUMO-1 and SUMO-
2/3 with CIN85. Endogenous staining of CIN85 in cultured, dif-
ferentiated CD2AP/ and CD2AP/ podocytes revealed a
vesicle-like distribution of CIN85 in the cytoplasm and a weak
nuclear expression in CD2AP/ podocytes. In CD2AP/ podo-
cytes, CIN85 was found at the plasma membrane and in the peri-
nuclear and nuclear regions (Fig. 4C). SUMO-1, SUMO-2/3, and
Ubc9 show nuclear expression. Furthermore, SUMO-1 and Ubc9
exhibited a cytoplasmic, vesicle-related distribution patternwhich
partially colocalizedwith CIN85 inCD2AP/ podocytes. Immu-
noprecipitation of CD2AP/ and CD2AP/ podocytes uncov-
ered an association of SUMO-1 and a weak association of
FIG 2 Full-length CIN85 is posttranslationally modified in CD2AP/ podocytes. (A) Protein lysates from two different clones of cultured differentiated
CD2AP/ and CD2AP/ podocytes were analyzed for CIN85, ubiquitin, CD2AP, and GAPDH expression by Western blotting (WB). The arrows show the
masses of proteins and specific isoforms of CIN85. (Below) Densitometry summarizing the means and standard deviations of 200-, 130-, and 85-kDa CIN85/
GAPDHobtained from three independent experiments.OD, optical density. *,P 0.0005 compared to thewild type/knockout (WT/KO) by Student’s t test; n.s.,
not significant. (B) PCR was performed on cDNA generated from cultured differentiated CD2AP/ and CD2AP/ podocytes. Mouse-specific primers m1
(positioned in exon 1) andmmn (positioned in exon 9) were used for amplification of the 5= region of CIN85 (lanes 1 and 2). Primerm6 (positioned in exon 19)
and mc (positioned in exon 24) were used for amplification of the 3= region of CIN85, including the coiled-coil (CC) domain (lanes 4 and 5). PCR primers m1,
mmn, mc, and m6 were used as described previously (3, 10). Lanes 3 and 6, negative control. The arrows show amplified cDNAs (a, b, and c): a, 5= region of
CIN85; b, full-length 3= region of CIN85; c, 3= region of CIN85exon21. (Bottom) Hypoxanthin-phosphoribosyl transferase 1 (HPRT-1) as a loading control.
(Below) Densitometry summarizing the means and standard deviations of amplified cDNAs a and b/c obtained from three independent experiments.
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SUMO-2/3 with the 130-kDa form of CIN85 in CD2AP/ podo-
cytes, whereas CD2AP/ podocytes showed no binding (Fig.
4D). Previously, we demonstrated that expression of the 85-kDa
full-length formofCIN85 leads to enhanced endocytosis of the slit
diaphragm protein nephrin in the absence of CD2AP (49). Sub-
cellular fractionation showed that the 130-kDa form of CIN85 is
mostly expressed in the cytosol and nucleus of CD2AP/ podo-
cytes, whereas the 85-kDa formofCIN85 is expressed in themem-
brane and nuclear fractions of CD2AP/ podocytes. Expression
of nephrin is restricted to the membrane fraction of CD2AP/
podocytes, whereas in CD2AP/ podocytes, expression of neph-
rin in the membrane fraction is significantly decreased (Fig. 4E).
CIN85 ismodifiedbySUMO-1, -2, and -3 in vitro.To evaluate
in detail whether CIN85 is modified by SUMO, we cotransfected
HEK 293 cells with CIN85-Flag; SUMO-1, -2, or -3; or EGFP–
SUMO-1 and HA-Ubc9. Immunoblotting of total cell lysates re-
vealed that CIN85 is SUMOylated by SUMO-1, -2, and -3 and
EGFP–SUMO-1 in the coexpression of the SUMOE2-conjugating
FIG 3 Modification of full-length CIN85 depends on expression of CD2AP. (A) pcDNA3.1, CD2AP/ podocytes were transiently transfected with myc-
CD2AP or empty vector pcDNA3.1, and whole-cell lysates were immunoblotted for CIN85, Myc, and GAPDH. Densitometry summarizing the means and
standard deviations of 130- and 85-kDa CIN85/GAPDH obtained from three independent experiments. *, P 0.008 compared to pcDNA3.1/myc-CD2AP by
Student’s t test. (B) Undifferentiated CD2AP/ podocytes were treated with 20 pmol of CD2AP siRNA or control siRNA (scrambled sequence); cultured for 0,
2, 4, and 8 days at 37°C for differentiation; and analyzed forCIN85, CD2AP, andGAPDH. (Right)Densitometry summarizing themeans and standard deviations
of 85-kDa CIN85/GAPDHobtained from three independent experiments. *, P 0.0003 compared to CD2AP siRNA/control siRNA by Student’s t test. (C) PCR
was performed on cDNA generated from CD2AP/ and CD2AP/ podocytes differentiated for 0, 2, 4, and 8 days. Amplified cDNAs show the full-length 3=
region of CIN85 (top) and HPRT-1 as a loading control.
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FIG 4 SUMOylation of CIN85 in CD2AP/ podocytes in vivo. (A) Fluorescence labeling demonstrates CIN85 (red) and CD2AP, SUMO-1 and -2/3, and Ubc9
(green) in renal cortex sections of 4-week-old CD2AP/ and CD2AP/mice. Colocalization of the indicated proteins resulted in yellow fluorescence in the
merged pictures. (B) Whole lysates from isolated CD2AP/ and CD2AP/ glomeruli were precipitated (IP) with SUMO-1 and -2/3 antibodies. The probes
were blotted and analyzed for CIN85. For IgG control, glomerular lysates from CD2AP/ mice were incubated with normal rabbit IgG instead of specific
antibody. The lysates were analyzed for CIN85, CD2AP, and GAPDH as a control. (C) Fluorescence labeling of differentiated CD2AP/ and CD2AP/
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enzyme Ubc9 (Fig. 5A). As depicted, a slowly migrating band was
observed with an apparent size that was compatible with a single
SUMO conjugated to CIN85-Flag. Interestingly, SUMOylation
through SUMO-3 is stronger than through SUMO-1 and -2. No
band of that size was observed in the absence of Ubc9. Further-
more, a possible SUMO chain formation is apparent for SUMO-1
and SUMO-2 and strongly for SUMO-3. All three SUMO family
members are able tomultimerize in vitro (9, 47). An EGFP-tagged
SUMO-1 construct leads to a band with a higher molecular mass
for SUMOylated CIN85, which proves that CIN85 is SUMOy-
lated. Interestingly, when we analyzed SUMOylation of CD2AP,
we also found that CD2AP is modified by SUMO-1, -2, and -3
whereas SUMOylation via SUMO-3 is stronger, similar to our
results with CIN85. Compared to CIN85, we can also show
SUMOylation of CD2AP and, furthermore, SUMO chain forma-
tions that are also apparent for CD2AP (Fig. 5B). Additionally, in
some experiments, the SUMOylation of CIN85 by SUMO-3
seemed to be enhanced in the presence of CD2AP (Fig. 5C). These
data, together with the analysis of the CD2AP/ and CD2AP/
mice and cultured podocytes, suggest that CIN85 and CD2AP can
be SUMOylated by SUMO-1 and -2 and more clearly by SUMO-3
and that SUMOylation of CIN85 is enhanced in the presence of
CD2AP. However, even though densitometric analysis in some ex-
periments revealed a clear trend for enhanced SUMOylation of
CIN85 in the presence of overexpressedCD2AP, these results did not
reach statistical significance inHEK293cells. This couldbe explained
by the fact that HEK 293 cells contain endogenous CD2AP levels
leading to a “baseline” SUMOylation effect that is only weakly en-
hanceable by overexpression of CD2AP.
SUMO-1, -2, and -3modify CIN85 on lysine 598. Tomap the
site on CIN85 that is modified by SUMOylation, we analyzed the
potential SUMOylation motifs using “SUMOplot prediction”
(55). There is one consensus SUMOylation sequence motif,
PKME, in mouse CIN85 where the lysine in position K598 is the
predicted acceptor site for SUMOylation. This motif is also con-
served in humanCIN85 (Fig. 6A). The lysine is positioned at the C
terminus of CIN85 right before the coiled-coil domain starts. To
explore whether this site is modified by SUMOylation, we gener-
ated a mutant of CIN85, CIN85K598R, where the lysine in position
598 was converted to arginine. CIN85-Flag or CIN85K598R-Flag
was cotransfected with SUMO-1, -2, or -3 and HA-Ubc9 in HEK
293 cells. We detected a slowly migrating band that was only ob-
served for wild-type CIN85 and, additionally, SUMO chain for-
mation for SUMO-2 and -3 (Fig. 6B). In contrast, this band was
absent when CIN85K598R was used as a substrate, suggesting that
conversion of lysine 598 to arginine abrogates SUMOylation of
CIN85. To assess if SUMOylation of CIN85 influences binding to
nephrin, we cotransfected nephrin-GFPwith wild-type ormutant
Flag-CIN85. As demonstrated in Fig. 6C, binding of nephrin to
mutant CIN85 is stronger, suggesting that SUMOylation of
CIN85 decreases binding to nephrin. To explore whether en-
hanced binding of nephrin to the K598R mutant is related to a
changed localization pattern of CIN85, we transfected podocytes
with wild-type or K598R GFP-CIN85 and examined the distribu-
tion by using immunofluorescence microscopy. We found that
wild-type CIN85-GFP displayed a strictly vesicular intracellular
distribution pattern in large perinuclear vesicles. In contrast,
K598R CIN85 mutant expression was found in smaller vesicles,
and some of these vesicles were detectable in a plasmamembrane-
associated localization pattern. Moreover, a partial overlap with
nephrin could be detected in some of the K598R CIN85 mutant
vesicles (Fig. 6D). These data indicate that SUMOylation of
CIN85 can directly influence the intracellular expression pattern
of CIN85 and its interaction with nephrin at the plasma mem-
brane.
DISCUSSION
CD2AP and CIN85 are gene duplicates of one another (paral-
ogues) whose origin can be traced to the early stages of vertebrate
evolution, before the separation between cartilaginous and bony
fish. As expected of gene duplicates, they contain very similar do-
main structures with similar promiscuous protein-protein bind-
ingmotifs. Nevertheless, they have been shown to have completely
different functions, particularly in podocytes. CD2AP is expressed
as a single protein band and is perceived as a “stabilizing” adaptor
in podocytes that connects the slit diaphragm to the actin cyto-
skeleton. In contrast, CIN85 is an adaptor protein that is known to
influence multiple processes. This is most likely due to a specific
spatial and temporal pattern of expression, a complex pattern of
pre-mRNA splicing, protein interactions, and posttranslational
modifications (7, 26, 45, 53). Interestingly, Cindr, the singleton
orthologue of CD2AP and CIN85 inDrosophila melanogaster, dis-
plays four splice variants. In comparison, CIN85 displays 10 splice
variants, which encode proteins, indicating a highly specific
evolved role for each variant in different tissues and cell lines (3,
31). Our previous work suggests that expression of full-length
CIN85 protein has a negative impact on podocyte survival signal-
ing and slit diaphragm integrity. Thus, we wanted to analyze
whether these closely related proteins influence each other’s ex-
pression in the cell to understand how this protein balance is reg-
ulated. It is known that regulatory networks that evolved, at least
in part, through gene duplication events are not exclusively regu-
lated at transcription initiation but instead are regulated post-
translationally via protein-protein interactions (30). For example,
the activity of AIB1, a member of the steroid receptor coactivator
(SRC) family, is inhibited by SUMOylation, which is in contrast to
SUMOylation of its parologues GRIP1 and SRC-1 (54), where
SUMOylation leads to an enhancement of function. In this report,
we present evidence that CIN85 is modified by SUMO-1, -2, and
-3 in the presence of CD2AP, and we analyze the functional con-
sequences of SUMOylation. When we compared the protein ex-
pression of CIN85 in CD2AP/ and CD2AP/ podocytes we
observed several CIN85 isoforms in both cell types, but full-length
CIN85 was expressed only in CD2AP/ podocytes. Instead,
podocytes demonstrates CIN85 (green) and SUMO-1 and -2/3 andUbc9 (red). Colocalization resulted in yellow fluorescence in themerged pictures. The arrows
indicate colocalization in CD2AP/ podocytes and membrane distribution of CIN85 in CD2AP/ podocytes. (D) Whole lysates from differentiated
CD2AP/ and CD2AP/ podocytes were precipitated (IP) with SUMO-1 and -2/3. The probes were blotted and analyzed for CIN85. For IgG control, lysates
fromCD2AP/ podocytes were incubated with normal rabbit IgG instead of antibody. The lysates were analyzed for CIN85, CD2AP, and GAPDH as a control.
The asterisks in panels B andDmark nonspecific IgG heavy-chain bands. (E) Subcellular fractionation of CD2AP/ andCD2AP/ podocytes intomembrane,
cytosolic, and nuclear fractions showing expression of CIN85 and nephrin. As a control, membrane fractions were analyzed for Gi3, cytosolic fractions were
analyzed for GAPDH, and nuclear fractions were analyzed for histone H1.
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CD2AP/ podocytes show a strong band of approximately 130
kDa. Expression analysis of mRNA showed no differences be-
tween CD2AP/ and CD2AP/ podocytes, suggesting that the
differences are caused by posttranslational modification influ-
enced by the presence of CD2AP. This doublet protein band was
also observed by other groups and was described as ubiquitinated
full-length CIN85 (31, 51). Interestingly, several protein bands
were observed migrating beneath the 130-kDa form, suggesting
that there could be a “step-by-step”modification. However, over-
expression of CD2AP in CD2AP-deficient podocytes enhanced
the formation of modified CIN85, underlining the fact that
CD2AP is involved in regulation of CIN85 modification.
Previously, we demonstrated that full-length CIN85 expres-
sion is differentiation dependently upregulated in CD2AP/
podocytes (48). Consistent with the previous results, inhibition of
CD2AP protein expression by siRNA in CD2AP/ podocytes led
to differentiation-dependent upregulation of the 85-kDa full-
length form of CIN85. Interestingly, CD2AP/ podocytes
treated with a control siRNA show differentiation-dependent up-
regulation of the 130-kDa form of CIN85, confirming that the
presence of CD2AP leads to posttranslationalmodification of full-
length CIN85 in podocytes.
Numerous proteins have been shown to associate with both
CIN85 and CD2AP, which can be explained by the sequence and
structural similarities (7). Many of these proteins, including p130
Cas, Crk, and p85 phosphatidylinositol-3 kinase (PI3K), are adap-
tormolecules linked to protein kinase pathways (1, 18, 23, 31, 53).
Given these facts, Grunkemeyer et al. proposed that CIN85 may
compensate for the loss of CD2AP in CD2AP/ podocytes (13).
Our previous findings underline the fact that expression of full-
length CIN85 leads to decreased survival signaling in CD2AP/
podocytes (48).
It is known that CIN85 is ubiquitinated but not degraded by
the proteasome, suggesting that ubiquitination may regulate en-
docytotic or interaction activity of CIN85 (15, 51). Due to the
mass shift of 45 kDa, a single monoubiquitination probably is not
the only possible posttranslational modification of CIN85. We
report in this study that CIN85 is SUMOylated in vivo by SUMO-1
and SUMO-2/3 in glomeruli fromCD2AP/mice and in vitro in
culturedCD2AP/ podocytes ofmice, andwe identified the 130-
kDa form as SUMOylated CIN85. Glomeruli of CD2AP/mice
display increased expression of CIN85 compared to CD2AP/
mice that is not evenly distributed and might contribute to glo-
merular injury. Cultured CD2AP/ and CD2AP/ podocytes
show no quantitative difference in CIN85 expression but a differ-
ence in its distribution. CIN85 is expressed in CD2AP/ podo-
cytes mainly in the cytosol and nucleus, whereas CD2AP/
podocytes reveal a membrane and nuclear expression pattern.
Previously, we demonstrated that CIN85 is a binding partner of
nephrin and thereby enhances endocytosis of nephrin in
CD2AP/ podocytes (49). We showed in this study that expres-
sion of nephrin is strongly decreased in the membrane fraction of
CD2AP/ podocytes and that 85-kDa full-length CIN85 is si-
multaneously strongly expressed. These observations underline
our previous studies showing that full-length CIN85 leads to
downregulation of nephrin. Modified CIN85, expressed as a 130-
kDa band, cannot be found in the membranes of CD2AP/
podocytes but only in the cytosol. This indicates that
SUMOylation of CIN85 leads to stable localization of CIN85 in
the cytosol, where it cannot bind to nephrin. Additionally, CIN85
FIG 5 SUMOylation of CIN85 and of CD2AP in vitro. HEK 293 cells were
cotransfected with plasmids expressing Flag-CIN85 (A) or Myc-CD2AP (B);
untagged Sumo-1, -2, and -3; HA-Ubc9; and EGFP-tagged-SUMO-1. Whole-
cell lysates were immunoblotted with anti-Flag, anti-Myc, or anti-HA anti-
body. (Below) Densitometry summarizing the means and standard deviations
of SUMO-1-, -2-, and -3-modified/unmodified CIN85 or CD2AP (S1,
SUMO-1; S2, SUMO-2; S3, SUMO-3) obtained from three independent ex-
periments. *, P 0.04 compared to S2/S3 by Student’s t test. (C)HEK 293 cells
were cotransfected with Flag-CIN85, Myc-CD2AP, untagged SUMO-3, and
HA-Ubc9. Whole-cell lysates were immunoblotted with anti-Flag (top) or
anti-Myc and anti-HA antibody (bottom). (Below) Densitometry summariz-
ing the means and standard deviations of SUMO-3-modified/unmodified
CIN85 (gray bars, without myc-CD2AP; white bars, with myc-CD2AP) ob-
tained from three independent experiments. *, P  0.1 by Student’s t test;
n.s., not significant. The arrows show expression of un-SUMOylated and
SUMOylated protein.
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is expressed in CD2AP/ and CD2AP/ podocytes in the nu-
clear fraction. The localization of CIN85 in the nucleus was first
observed by our group, but the function of nuclear localization is
not known. Furthermore, SUMO-1 and Ubc9 are expressed in
glomeruli and in cultured podocytes in the nucleus, but also in the
cytosol, which was also shown for MDCK cells (5), underlining
the fact that SUMOylation of CIN85 could also occur in the cyto-
sol. Overexpression studies in HEK 293T cells demonstrated that
CIN85 is a SUMO target with preferential binding to SUMO-3
compared to SUMO-1 and -2. Although endogenous binding as-
says show no preference of CIN85 for binding to SUMO-2/3 and
most data of other groups suggest that the SUMO conjugation
apparatus is incapable of discriminating between SUMO iso-
forms, a preferred interaction with SUMO-3 compared to
FIG 6 Identification of the SUMOmodification site in mouse CIN85. (A) Schematic representation of the putative SUMO site in murine CIN85, where lysine
in position 598 is the putative acceptor amino acid. The consensus SUMOylation sequence is PKME, where P is a large hydrophobic amino acid, K is the
SUMO-modified lysine residue, and E is an acidic residue. (B) HEK 293 cells were transfected with Flag-CIN85; Flag-CIN85K598R; or untagged SUMO-1, -2, and
-3 and were immunoblotted with anti-Flag antibody. The arrows show un-SUMOylated and SUMOylated protein. The immunoblot represents the results of
three independent experiments. (C) HEK 293 cells were transfected with Flag-CIN85, Flag-CIN85K598R, or pcDNA3.1 empty vector and GFP-nephrin. Whole-
cell lysates were subjected to immunoprecipitation (IP) with Flag-coupled beads or, for the isotope-matched control, with normal mouse IgG and agarose beads
and immunoblotted with anti-GFP or anti-Flag antibody. As a control, the lysates were immunoblotted with anti-Flag or anti-GFP. (Below) Densitometry
summarizing the means and standard deviations of immunoprecipitated nephrin/nephrin in control lysates obtained from three independent experiments.
*, P 0.001 compared to Flag-CIN85/Flag-CIN85K598R by Student’s t test. (D) Podocytes were transfected with plasmids expressing GFP-tagged wild-type or
mutant CIN85K598R (green) and SV5-nephrin (red). After 48 h, the transfected cells were analyzed by fluorescence microscopy. The nucleus was stained with
DAPI (blue). Overlap of CIN85K598R and SV5-nephrin is indicated by the arrows.
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SUMO-1was shown forUSP25, a ubiquitin-specific protease (32–
34). Furthermore, CD2AP could be identified as a SUMO target.
Together with the finding of CIN85 SUMOylation in CD2AP/
podocytes in contrast to non-SUMOylated CIN85 in CD2AP/
podocytes, this led us to the hypothesis that SUMOylation of
CD2AP could probably enhance SUMOylation of CIN85. A sim-
ilar phenomenon has also been described for other proteins, like
SF2/ASF (36). Interestingly, it has been shown that CD2AP and
CIN85 homodimerized via their coiled-coil domains (23).
Whenwe performedmutagenesis analysis, we demonstrated that
conversion of lysine 598 to arginine, which is part of a SUMO con-
sensus sequence, completely blocked SUMOylation of CIN85. Re-
markably, thisSUMOylationmotif lieswithina serine-richpartof the
C terminus. Serine residues are suggested to regulate SUMObinding
by phosphorylation, as a negative charge strengthens SUMO (Ubc9)
binding (11). The complete blocking of SUMOylation indicates that
lysine 598 is the only acceptor site of CIN85.
Furthermore, our findings revealed thatmutation of CIN85 on
lysine 598 led to increased plasma membrane-associated localiza-
tion and increased binding to nephrin. These findings are also
consistent with endogenously expressed CIN85, whose modified
form is expressed in the cytosol but not in the membrane. Thus,
the effect of CIN85 SUMOylation could be due to a changed lo-
calization pattern. SUMOylation and ubiquitination have also
been reported to act either sequentially or in concert to regulate
the substrate protein (4, 17), suggesting that both also participate
in regulating CIN85 activity. Given the fact that the presence of
CD2AP led to enhanced posttranslational modification of CIN85
and abolished SUMOylation-enhanced binding to nephrin, we
hypothesize that the activity of CIN85 is decreased in podocytes
expressing CD2AP. Although SUMOylation and de-SUMOylation
are dynamic processes, CD2AP/ podocytes show constant
SUMOylation of CIN85. Lin et al. reported constant
SUMOylation of Smad4 that protects it from ubiquitin-
dependent degradation and controls subcellular localization (27).
Constant SUMOylation could control the stable cytosolic local-
ization of CIN85 in CD2AP/ podocytes and may simultane-
ously prevent ubiquitin-dependent degradation. For the tumor
suppressor p53, it has been demonstrated that ubiquitination si-
multaneously enhances SUMOylation, thus driving its nuclear ex-
port (4, 17).
We conclude from our experiments that SUMOylation of
CIN85 could be an important molecular switch regulating the
binding activity of CIN85 to nephrin by determining its subcellu-
lar localization. Thus, SUMOylation of CIN85 could regulate slit
diaphragm stability and turnover of slit diaphragm molecules.
ACKNOWLEDGMENTS
We thank Germaine Puncha and Sandy Zachura for excellent technical
assistance, Ivan Dikic (Frankfurt, Germany) for providing the CIN85-CT
antibody and the CIN85-GFP construct, and Tobias Huber (Freiburg,
Germany) for providing the SV5-nephrin constructs.
This work was supported by an Emmy Noether Fellowship to M.S.
granted by the Deutsche Forschungsgemeinschaft (SCHI 587/2-2) and
SFB 566, Project B16. B.L.K. was supported by award number
P20RR016463 from the National Center for Research Resources.
The content is solely our responsibility and does not necessarily rep-
resent the official views of the National Center for Research Resources or
the National Institutes of Health.
REFERENCES
1. Borinstein SC, et al. 2000. SETA is a multifunctional adapter protein with
three SH3 domains that binds Grb2, Cbl, and the novel SB1 proteins. Cell
Signal. 12:769–779.
2. Bruck S, et al. 2006. Identification of a novel inhibitory actin-capping
protein binding motif in CD2-associated protein. J. Biol. Chem. 281:
19196–19203.
3. Buchman VL, Luke C, Borthwick EB, Gout I, Ninkina N. 2002. Orga-
nization of the mouse Ruk locus and expression of isoforms in mouse
tissues. Gene 295:13–17.
4. Carter S, Bischof O, Dejean A, Vousden KH. 2007. C-terminal modifi-
cations regulate MDM2 dissociation and nuclear export of p53. Nat. Cell
Biol. 9:428–435.
5. Collec E, et al. 2007. Ubc9 interacts with Lu/BCAM adhesion glycopro-
teins and regulates their stability at the membrane of polarized MDCK
cells. Biochem. J. 402:311–319.
6. Dehal P, Boore JL. 2005. Two rounds of whole genome duplication in the
ancestral vertebrate. PLoS Biol. 3:e314.
7. Dikic I. 2002. CIN85/CMS family of adaptor molecules. FEBS Lett. 529:
110–115.
8. Farrow NA, et al. 1994. Backbone dynamics of a free and
phosphopeptide-complexed Src homology 2 domain studied by 15N
NMR relaxation. Biochemistry 33:5984–6003.
9. Fu C, et al. 2005. Stabilization of PML nuclear localization by conjugation
and oligomerization of SUMO-3. Oncogene 24:5401–5413.
10. Gaidos G, Soni S, Oswald DJ, Toselli PA, Kirsch KH. 2007. Structure
and function analysis of the CMS/CIN85 protein family identifies actin-
bundling properties and heterotypic-complex formation. J. Cell Sci. 120:
2366–2377.
11. Geiss-Friedlander R, Melchior F. 2007. Concepts in sumoylation: a de-
cade on. Nat. Rev. Mol. Cell Biol. 8:947–956.
12. Gout I, et al. 2000. Negative regulation of PI 3-kinase by Ruk, a novel
adaptor protein. EMBO J. 19:4015–4025.
13. Grunkemeyer JA, Kwoh C, Huber TB, Shaw AS. 2005. CD2-associated
protein (CD2AP) expression in podocytes rescues lethality of CD2AP de-
ficiency. J. Biol. Chem. 280:29677–29681.
14. Haglund K, Shimokawa N, Szymkiewicz I, Dikic I. 2002. Cbl-directed
monoubiquitination of CIN85 is involved in regulation of ligand-induced
degradation of EGF receptors. Proc. Natl. Acad. Sci. U. S. A. 99:12191–
12196.
15. Havrylov S, Redowicz MJ, Buchman VL. 2010. Emerging roles of Ruk/
CIN85 in vesicle-mediated transport, adhesion, migration and malig-
nancy. Traffic 11:721–731.
16. Hernandez-Valladares M, et al. 2010. Structural characterization of a
capping protein interaction motif defines a family of actin filament regu-
lators. Nat. Struct. Mol. Biol. 17:497–503.
17. Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. 2003. Se-
quential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin
mediates NF-kappaB activation by genotoxic stress. Cell 115:565–576.
18. Huber TB, et al. 2003. Nephrin and CD2AP associate with phosphoino-
sitide 3-OH kinase and stimulate AKT-dependent signaling. Mol. Cell
Biol. 23:4917–4928.
19. Johnson ES. 2004. Protein modification by SUMO. Annu. Rev. Biochem.
73:355–382.
20. Kaneko T, et al. 2005. Rho mediates endocytosis of epidermal growth
factor receptor through phosphorylation of endophilin A1 by Rho-kinase.
Genes Cells 10:973–987.
21. Kerscher O, Felberbaum R, Hochstrasser M. 2006. Modification of
proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev.
Biol. 22:159–180.
22. Kestila M, et al. 1998. Positionally cloned gene for a novel glomerular
protein—nephrin—is mutated in congenital nephrotic syndrome. Mol.
Cell 1:575–582.
23. Kirsch KH, Georgescu MM, Ishimaru S, Hanafusa H. 1999. CMS: an
adapter molecule involved in cytoskeletal rearrangements. Proc. Natl.
Acad. Sci. U. S. A. 96:6211–6216.
24. Kobayashi S, Sawano A, Nojima Y, Shibuya M, Maru Y. 2004. The
c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degra-
dation of Flt-1 (VEGFR-1). FASEB J. 18:929–931.
25. Konishi H, et al. 2006. CFBP is a novel tyrosine-phosphorylated protein
that might function as a regulator of CIN85/CD2AP. J. Biol. Chem. 281:
28919–28931.
Tossidou et al.
1078 mcb.asm.org Molecular and Cellular Biology
26. Kowanetz K, et al. 2004. CIN85 associates with multiple effectors con-
trolling intracellular trafficking of epidermal growth factor receptors.
Mol. Biol. Cell 15:3155–3166.
27. Lin X, Liang M, Liang YY, Brunicardi FC, Feng XH. 2003. SUMO-1/
Ubc9 promotes nuclear accumulation and metabolic stability of tumor
suppressor Smad4. J. Biol. Chem. 278:31043–31048.
28. LinX, et al.2003.Opposed regulationof corepressorCtBPbySUMOylationand
PDZbinding.Mol. Cell 11:1389–1396.
29. Lynch DK, et al. 2003. A Cortactin-CD2-associated protein (CD2AP)
complex provides a novel link between epidermal growth factor receptor
endocytosis and the actin cytoskeleton. J. Biol. Chem. 278:21805–21813.
30. Martinez-Nunez MA, Perez-Rueda E, Gutierrez-Rios RM, Merino E.
2010. New insights into the regulatory networks of paralogous genes in
bacteria. Microbiology 156:14–22.
31. Mayevska O, et al. 2006. Expression of adaptor protein Ruk/CIN85 iso-
forms in cell lines of various tissue origins and human melanoma. Exp.
Oncol. 28:275–281.
32. Meulmeester E, Kunze M, Hsiao HH, Urlaub H, Melchior F. 2008.
Mechanism and consequences for paralog-specific sumoylation of
ubiquitin-specific protease 25. Mol. Cell 30:610–619.
33. Meulmeester E, Melchior F. 2008. Cell biology: SUMO. Nature 452:709–
711.
34. Mohideen F, Lima CD. 2008. SUMO takes control of a ubiquitin-specific
protease. Mol. Cell 30:539–540.
35. Muller S, Ledl A, Schmidt D. 2004. SUMO: a regulator of gene expression
and genome integrity. Oncogene 23:1998–2008.
36. Pelisch F, et al. 2010. The serine/arginine-rich protein SF2/ASF regulates
protein sumoylation. Proc. Natl. Acad. Sci. U. S. A. 107:16119–16124.
37. Peterson KJ, Eernisse DJ. 2001. Animal phylogeny and the ancestry of
bilaterians: inferences from morphology and 18S rDNA gene sequences.
Evol. Dev. 3:170–205.
38. Pichler A, Knipscheer P, Saitoh H, Sixma TK, Melchior F. 2004. The
RanBP2 SUMO E3 ligase is neither. Nat. Struct. Mol. Biol. 11:984–991.
39. Pickart CM. 2001. Mechanisms underlying ubiquitination. Annu. Rev.
Biochem. 70:503–533.
40. Putaala H, Soininen R, Kilpelainen P, Wartiovaara J, Tryggvason K.
2001. The murine nephrin gene is specifically expressed in kidney, brain
and pancreas: inactivation of the gene leads to massive proteinuria and
neonatal death. Hum. Mol. Genet. 10:1–8.
41. Sampson DA, Wang M, Matunis MJ. 2001. The small ubiquitin-like
modifier-1 (SUMO-1) consensus sequence mediates Ubc9 binding and is
essential for SUMO-1 modification. J. Biol. Chem. 276:21664–21669.
42. Sato Y, et al. 2007. Regulation of the interaction of Disabled-1 with CIN85
by phosphorylationwithCyclin-dependent kinase 5.GenesCells 12:1315–
1327.
43. Schroeder B, Weller SG, Chen J, Billadeau D, McNiven MA. 2010. A
Dyn2-CIN85 complex mediates degradative traffic of the EGFR by regu-
lation of late endosomal budding. EMBO J. 29:3039–3053.
44. Shih NY, et al. 2001. CD2AP localizes to the slit diaphragm and binds to
nephrin via a novel C-terminal domain. Am. J. Pathol. 159:2303–2308.
45. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I. 2002.
Cbl-CIN85-endophilin complex mediates ligand-induced downregula-
tion of EGF receptors. Nature 416:183–187.
46. Swanson KA, Kang RS, Stamenova SD, Hicke L, Radhakrishnan I. 2003.
Solution structure of Vps27 UIM-ubiquitin complex important for endo-
somal sorting and receptor downregulation. EMBO J. 22:4597–4606.
47. Tatham MH, et al. 2001. Polymeric chains of SUMO-2 and SUMO-3 are
conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem.
276:35368–35374.
48. Tossidou I, et al. 2007. CD2AP/CIN85 balance determines receptor ty-
rosine kinase signaling response in podocytes. J. Biol. Chem. 282:7457–
7464.
49. Tossidou I, et al. 2010. CIN85/RukL is a novel binding partner of nephrin
and podocin and mediates slit diaphragm turnover in podocytes. J. Biol.
Chem. 285:25285–25295.
50. van Duijn TJ, Anthony EC, Hensbergen PJ, Deelder AM, Hordijk PL.
2010. Rac1 recruits the adapter protein CMS/CD2AP to cell-cell contacts.
J. Biol. Chem. 285:20137–20146.
51. Verdier F, et al. 2002. Ruk is ubiquitinated but not degraded by the
proteasome. Eur. J. Biochem. 269:3402–3408.
52. Wakasaki T, et al. 2010. A critical role of c-Cbl-interacting protein of 85
kDa in the development and progression of head and neck squamous cell
carcinomas through the ras-ERK pathway. Neoplasia 12:789–796.
53. Watanabe S, et al. 2000. Characterization of the CIN85 adaptor protein
and identification of components involved in CIN85 complexes.
Biochem. Biophys. Res. Commun. 278:167–174.
54. WuH, et al. 2006. Coordinated regulation of AIB1 transcriptional activity
by sumoylation and phosphorylation. J. Biol. Chem. 281:21848–21856.
55. Xue Y, Zhou F, Fu C, Xu Y, Yao X. 2006. SUMOsp: a web server for
sumoylation site prediction. Nucleic Acids Res. 34:W254–W257.
56. Yang SH, Jaffray E, Hay RT, Sharrocks AD. 2003. Dynamic interplay of
the SUMO and ERK pathways in regulating Elk-1 transcriptional activity.
Mol. Cell 12:63–74.
57. Yoon HY, Kales SC, Luo R, Lipkowitz S, Randazzo PA. 2011. ARAP1
association with CIN85 affects epidermal growth factor receptor endo-
cytic trafficking. Biol. Cell 103:171–184.
SUMOylation of CIN85
March 2012 Volume 32 Number 6 mcb.asm.org 1079
